AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01870895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral
Study NCT01870895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT03588143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Two kinds of electrical stimulation (TENS and HVPS) and placebo intervention
Study NCT03588143 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation
Description: Two kinds of electrical stimulation (TENS and HVPS) and placebo intervention
Study NCT03588143 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical stimulation
Description: Two kinds of electrical stimulation (TENS and HVPS) and placebo intervention
Study NCT02000791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison of fibreoptic view
Study NCT02000791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of fibreoptic view
Study NCT00528047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRLX 93936
Description: PRLX 93936 will be administered intravenously over one hour daily for 5 days.
Study NCT01207180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call follow-up
Description: A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.
Study NCT01207180 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Satisfaction survey
Description: Patients will be given a satisfaction survey.
Study NCT01207180 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group --- no intervention
Description: Control group
Study NCT02769910 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capsaicin 1 Hour
Description: Dermal patches for transdermal application of Capsaicin, applied for 1 hour
Study NCT02769910 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qutenza Demo Patch
Description: Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.
Study NCT03876119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarterial alteplase
Description: See arm/group descriptions.
Study NCT03876119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm/group descriptions.
Study NCT00193206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
Study NCT00193206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
Study NCT00193206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound Paclitaxel
Description: ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
Study NCT03067389 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: Genetic diagnostic test
Study NCT01694147 — intervention group
Intervention type: DEVICE
Intervention: PiCCO monitoring system
Description: The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
Study NCT01633658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: a single dose of 2500 micrograms of cholecalciferol
Study NCT01633658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25(OH)D
Description: a single dose of 625 micrograms of 25(OH)D
Study NCT02595255 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01189695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir
Description: Lopinavir/ritonavir 200/50 mg every 12 hours
Study NCT01189695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-boosted lopinavir
Description: Lopinavir/ritonavir 200/50 mg every 12 hours
Study NCT03158532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin I
Description: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Study NCT03158532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo I
Description: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Study NCT03158532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo I
Description: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Study NCT03158532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin II
Description: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Study NCT03158532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin II
Description: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Study NCT03158532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo II
Description: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Study NCT03158532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo II
Description: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Study NCT04387396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise specific to knee osteoarthritis.
Study NCT04424758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video information about mammography screening
Description: A video informing about mammography screening
Study NCT04424758 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Video information about smart energy systems
Description: A video informing about smart energy systems
Study NCT03844048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: oral; film-coated tablets or tablets for oral suspension
Study NCT01189695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimized background regimens (OBRs)
Description: Optimized background regimens such as NRTIs, etravirine or raltegravir
Study NCT04393259 — intervention group
Intervention type: OTHER
Intervention: Rainbow Clinic Model of Antenatal Care
Description: Rainbow Clinic Model is an antenatal model of care with initial ultrasound scan at 23 weeks' gestation including uterine artery Doppler, frequency of subsequent scans determined using data from this initial scan. Continuity of care is provided by obstetricians and midwives.
Study NCT02276274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-322-MET
Description: Oral administration of SYR-322-MET
Study NCT00105690 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telemedicine intervention
Study NCT03911401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% OPA-15406
Description: Twice daily
Study NCT03911401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPA-15406
Description: Twice daily
Study NCT03911401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Twice daily
Study NCT03339999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-242428
Description: AGN-242428 administered as an oral capsule(s) once daily.
Study NCT00785499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Milk Components and Metabolic syndrome
Description: 1 liter per day of the test drinks for 3 mo
Study NCT03081871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led cardiovascular risk service (CVRS)
Description: CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients. The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation. The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.
Study NCT03081871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led cardiovascular risk service (CVRS)
Description: CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients. The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation. The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.
Study NCT03081871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile access to study Personal Health Record
Description: Only subjects assigned to the intervention arm will have access to the mobile app version of the study personal Health Record.
Study NCT03081871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web access to study Personal Health Record
Description: Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
Study NCT03081871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web access to study Personal Health Record
Description: Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
Study NCT02233972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT02233972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Study NCT03339999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered as an oral capsule(s) once daily.
Study NCT03339999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as an oral capsule(s) once daily.
Study NCT00766870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA34893
Description: Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
Study NCT00766870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine extended release
Description: Per oral, once daily, during 8 weeks, followed by a two-week tapering period
Study NCT00766870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Per oral doses, twice daily as capsules during 10 weeks
Study NCT03081858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSD-001
Description: Administered via intravesical instillation.
Study NCT02440490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training
Study NCT02440490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video watching
Study NCT01463059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution for injection, administered as subcutaneous injections
Study NCT01463059 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection, administered as subcutaneous injections
Study NCT01463059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olokizumab 60 mg
Description: Olokizumab 60 mg solution for injection, administered as subcutaneous injections
Study NCT00785499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Milk Components and Metabolic syndrome
Description: 1 liter per day of the test drinks for 3 mo
Study NCT02233972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgolides Meglumine Injection
Study NCT01463059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olokizumab 120 mg
Description: Olokizumab 120 mg solution for injection, administered as subcutaneous injections
Study NCT01463059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olokizumab 240 mg
Description: Olokizumab 240 mg solution for injection, administered as subcutaneous injections
Study NCT00620126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UC Home Automated Telemanagement
Description: Weekly assessment with UC Home Automated Telemanagement
Study NCT00620126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Care
Description: Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
Study NCT02210559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 will be administered per dose and schedule specified in the arm group description.
Study NCT02210559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered per dose and schedule specified in the arm group description.
Study NCT02210559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered per dose and schedule specified in the arm group description.
Study NCT02132195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
Study NCT02210559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.
Study NCT02210559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.
Study NCT01734070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry consumption
Description: Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
Study NCT01254734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transoral robotic surgery
Description: Undergo transoral robotic microsurgery
Study NCT01254734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01254734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02883608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cap assisted forward-viewing endoscope
Description: a cap fitted to the to top of the forward-viewing endoscope
Study NCT02883608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cap assisted forward-viewing endoscope
Description: a cap fitted to the to top of the forward-viewing endoscope
Study NCT00857701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Extension Dynasplint
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
Study NCT03874091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral ESP block with 0,25% Bupivacaine+ Adrenaline
Description: Regional anaesthesia technique performed under ultrasound guidance before surgery
Study NCT03431688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAM
Description: treatment with PPI, metonidazole, amoxicillin
Study NCT03431688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PBMT
Description: treatment with PPI, metonidazole, bismuth, tetracyclin
Study NCT02810210 — intervention group
Intervention type: OTHER
Intervention: fundus examination
Description: In cohort 3, a fundus examination will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups.
Study NCT02810210 — intervention group
Intervention type: OTHER
Intervention: Head ultrasound
Description: In cohort 3, a head ultrasound will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups.
Study NCT02776631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinloc
Description: Internal fixation device
Study NCT02776631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hansson Pins (LIH)
Description: Internal fixation device
Study NCT03874091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block continuous infusion with 0,125% Bupivacaine+Adrenaline
Description: Continous infusion of Local Anaesthetic (LA) given postoperatively via the catheter.
Study NCT01460979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25mg weekly intravenous until progression
Study NCT03397472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic field modulation device
Description: use the device with magnetic field modulation to treat insomnia
Study NCT03397472 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo device
Description: use the sleep pillow without magnetic field modulation treatment
Study NCT02010099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP110 Gel
Study NCT02010099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP110 Medicated wipes
Study NCT02010099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preparation-H Cream
Study NCT01858675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarkers, red blood cells and plasma assessment
Study NCT00231959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole (Mirapex)
Description: pramipexole 0.5mg tablets qd and titrated per protocol
Study NCT00231959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill
Study NCT02233972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00614848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor drug eluting coronary stent
Description: Zotarolimus coated coronary stent (10ug/mm)
Study NCT00614848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endeavor drug eluting coronary stent
Description: Zotarolimus coated coronary stent (10ug/mm)
Study NCT02584504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Study NCT03514160 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group exercise
Description: Group exercise based on the American College of Sports Medicine guidelines.
Study NCT01734499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Class
Description: A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in.